fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Glucagon rdna origin

All injection strengths: general benefit

GlucaGen · DIN 02333619 · 1 mg/Vial · powder for injection, vial

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.Discontinued February 29, 2024 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-02-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
GlucaGen · DIN 02333619 Manufacturer: Novo Nordisk Canada Inc; listing date 2011-12-15 Health Canada: Cancelled post market since 2024-02-29 · brand GLUCAGEN · ATC H04AA01 GLUCAGON · form Powder for solution, Kit · route Intramuscular · ingredients GLUCAGON (RECOMBINANT DNA ORIGIN) (GLUCAGON HYDROCHLORIDE) 1 MG/VIAL · company Novo nordisk canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

GlucaGen: Formulary list price $108.33 per unit (the source does not state the unit; exact figure $108.3300). What the ministry pays, not the patient.

Ministry pays: $108.3300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333619)

Source record
DIN 02333619: GlucaGen Raw flags: sec3=Y Item: 920000643; group id 921; item number 2196; lccId None; manufacturer id NOO Source form: Inj Pd-Vial Pk; strength: 1mg/Vial Recorded listing: General benefit Source prices (unrounded): $108.3300; ministry $108.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333619 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81923
Shortage status: discontinued (February 29, 2024, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 29, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (H04AA): coverage varies; not interchangeable

  • Glucagon (Glucagon Injection Kit): limited Use 625, listing status unconfirmed
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

GLUCAGON

· 2 products · Temporary benefit (1), Limited Use, codes 625 (1) · strengths: 1mg/Vial, 3mg · Inj Pd-1mL Vial Pk (Kit), Nas Pd Device

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

GlucaGen · DIN 02333619 Shortage status: discontinued (2024-02-29, reported by NOVO NORDISK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333619

Check this DIN again